Riboxx PHARMACEUTICALS focuses on development of agonists of Toll-like Receptors (TLRs), with a direct application as modulators of innate immunity. TLR agonists increase or modulate immune response to an antigen. TLR agonists are therefore used as adjuvants in therapeutic vaccines (i.e. against cancer) and prophylactic vaccines (i.e. against infections).
Riboxx PHARMACEUTICALS engineers and manufactures TLR agonists in the highest possible quality and quantity. The proprietary molecule of Riboxx, Riboxxim®, triggers innate immune response through TLR3 activation, enabling novel vaccination approaches.